ArticleClinical and translational medicine2026
ADAMTS4 mediates LPS-induced cardiac injury and myocardial fibrosis through proteolytic cleavage of TSP1.
Article in Clinical and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Septic cardiomyopathy is characterized by acute cardiac dysfunction, while sustained inflammatory and extracellular matrix remodeling may contribute to subsequent myocardial fibrosis and impaired cardiac recovery. A disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4) has been linked to fibrotic remodelling, but its role in septic cardiac injury remains unclear. Here, we show that Adamts4 is upregulated in LPS-induced septic mouse hearts and is predominantly induced in cardiac fibroblasts. Using three fibroblast-lineage Adamts4 knockout models, we demonstrate that Adamts4 deletion attenuates LPS-induced cardiac dysfunction, inflammation and fibrosis, whereas Tcf21-lineage fibroblast Adamts4 overexpression aggravates these changes. Mechanistically, ADAMTS4 interacts with thrombospondin-1 (TSP1) and promotes its catalytic activity-dependent proteolytic processing. The 236-246 amino acid region of TSP1 is required for fragment generation and fibroblast activation. TSP1 processing further activates TGF-β/Smad and NF-κB signalling, promoting myofibroblast activation and extracellular matrix deposition. These findings identify ADAMTS4 as a fibroblast-centred driver of septic cardiac fibrosis and suggest that targeting the ADAMTS4-TSP1 axis may offer therapeutic potential for septic cardiomyopathy. KEY POINTS: ADAMTS4 is induced predominantly in cardiac fibroblasts after LPS challenge Fibroblast-lineage Adamts4 deletion attenuates LPS-induced cardiac dysfunction and fibrosis The TSP1 236-246 aa region is required for efficient ADAMTS4-dependent processing ADAMTS4-dependent TSP1 processing activates TGF-β/Smad and NF-κB signalling in fibroblasts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.